These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12225690)

  • 1. Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants.
    Katz MM; Halbreich UM; Bowden CL; Frazer A; Pinder RM; Rush AJ; Wheatley DP; Lebowitz BD
    Neuropsychopharmacology; 2002 Sep; 27(3):319-28. PubMed ID: 12225690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
    Khin NA; Kronstein PD; Yang P; Ishida E; Hung HM; Mathis MV; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antidepressants: problems in evaluation.
    Coppen A
    Adv Biochem Psychopharmacol; 1984; 39():289-92. PubMed ID: 6380224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA guidelines forthe clinical evaluation of psychotropic drugs--antidepressant and antianxiety drugs.
    Psychopharmacol Bull; 1978 Apr; 14(2):45-63. PubMed ID: 26103
    [No Abstract]   [Full Text] [Related]  

  • 10. How should efficacy be evaluated in randomized clinical trials of treatments for depression?
    Thase ME
    J Clin Psychiatry; 1999; 60 Suppl 4():23-31; discussion 32. PubMed ID: 10086480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors contributing to failed trials of new agents: can technology prevent some problems?
    Greist JH; Mundt JC; Kobak K
    J Clin Psychiatry; 2002; 63 Suppl 2():8-13. PubMed ID: 15453008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies.
    Gelenberg AJ; Thase ME; Meyer RE; Goodwin FK; Katz MM; Kraemer HC; Potter WZ; Shelton RC; Fava M; Khan A; Trivedi MH; Ninan PT; Mann JJ; Bergeson S; Endicott J; Kocsis JH; Leon AC; Manji HK; Rosenbaum JF
    J Clin Psychiatry; 2008 Oct; 69(10):1513-28. PubMed ID: 19192434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodologic problems of clinical investigations of antidepressants].
    Puzyński S
    Psychiatr Pol; 2005; 39(3):435-47. PubMed ID: 16149754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population?
    Akiskal HS; Benazzi F
    J Affect Disord; 2006 Aug; 94(1-3):105-10. PubMed ID: 16766043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for the patient who does not respond well to initial antidepressant therapy.
    Preskorn SH
    J Psychiatr Pract; 2009 May; 15(3):202-10. PubMed ID: 19461393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study designs and outcomes in antidepressant clinical trials.
    Khan A; Schwartz K
    Essent Psychopharmacol; 2005; 6(4):221-6. PubMed ID: 16041918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for shortening the duration of clinical trials of antidepressants and a proposed paradigm for such studies.
    Katz MM; Berman N; Bowden CL; Frazer A
    J Clin Psychopharmacol; 2015 Jun; 35(3):329-32. PubMed ID: 25874919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
    Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.